

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (Canceled)
2. (Currently amended) A bispecific antibody that ~~has an activity of functionally substituting~~ functionally substitutes for a ligand of a heterodimeric type I interferon receptor having a first polypeptide chain and a second polypeptide chain, wherein the antibody binds to each of the first and second polypeptide chains, and wherein the ligand is an interferon.
- 3-6. (Canceled)
7. (Currently amended) The antibody according to ~~claim 6~~ claim 2, wherein said type I interferon receptor comprises an AR1 chain and an AR2 chain.
8. (Canceled)
9. (Currently amended) The antibody according to ~~claim 8~~ claim 7, wherein said antibody comprises the variable region of an anti-AR1 chain antibody and the variable region of an anti-AR2 chain antibody.
10. (Currently amended) The antibody according to claim 9, wherein said antibody comprises an anti-AR1 chain antibody variable region comprising ~~the amino acid sequence of (a) below~~ the H chain variable region amino acid sequence described in SEQ ID NO: 1 and the L chain variable region amino acid sequence described in SEQ ID NO:2 and an anti-AR2 chain antibody variable region comprising the H chain variable region amino acid sequence described

in SEQ ID NO: 9 and the L chain variable region amino acid sequence described in SEQ ID NO: 10. the amino acid sequence of any of the following (b1) to (b10):

~~(a) the H chain variable region amino acid sequence described in SEQ ID NO: 1 and the L chain variable region amino acid sequence described in SEQ ID NO: 2;~~

~~(b1) the H chain variable region amino acid sequence described in SEQ ID NO: 7 and the L chain variable region amino acid sequence described in SEQ ID NO: 8;~~

~~(b2) the H chain variable region amino acid sequence described in SEQ ID NO: 9 and the L chain variable region amino acid sequence described in SEQ ID NO: 10;~~

~~(b3) the H chain variable region amino acid sequence described in SEQ ID NO: 19 and the L chain variable region amino acid sequence described in SEQ ID NO: 20;~~

~~(b4) the H chain variable region amino acid sequence described in SEQ ID NO: 13 and the L chain variable region amino acid sequence described in SEQ ID NO: 14;~~

~~(b5) the H chain variable region amino acid sequence described in SEQ ID NO: 23 and the L chain variable region amino acid sequence described in SEQ ID NO: 24;~~

~~(b6) the H chain variable region amino acid sequence described in SEQ ID NO: 5 and the L chain variable region amino acid sequence described in SEQ ID NO: 6;~~

~~(b7) the H chain variable region amino acid sequence described in SEQ ID NO: 17 and the L chain variable region amino acid sequence described in SEQ ID NO: 18;~~

~~(b8) the H chain variable region amino acid sequence described in SEQ ID NO: 15 and the L chain variable region amino acid sequence described in SEQ ID NO: 16;~~

~~(b9) the H chain variable region amino acid sequence described in SEQ ID NO: 21 and the L chain variable region amino acid sequence described in SEQ ID NO: 22;~~

~~(b10) the H chain variable region amino acid sequence described in SEQ ID NO: 11 and the L chain variable region amino acid sequence described in SEQ ID NO: 12.~~

11. (Currently amended) The antibody according to claim 9, wherein said antibody comprises an anti-AR1 chain antibody variable region comprising ~~the amino acid sequence of (a) below the H chain variable region amino acid sequence described in SEQ ID NO: 3 and the L chain variable region amino acid sequence described in SEQ ID NO: 4~~ or an anti-AR2 chain antibody variable region comprising ~~the H chain variable region amino acid sequence described in SEQ ID NO: 9 and the L chain variable region amino acid sequence described in SEQ ID NO: 10.~~ the amino acid sequence of any of the following (b1) to (b3):

~~(a) the H chain variable region amino acid sequence described in SEQ ID NO: 3 and the L chain variable region amino acid sequence described in SEQ ID NO: 4;~~

~~(b1) the H chain variable region amino acid sequence described in SEQ ID NO: 25 and the L chain variable region amino acid sequence described in SEQ ID NO: 26;~~

~~(b2) the H chain variable region amino acid sequence described in SEQ ID NO: 9 and the L chain variable region amino acid sequence described in SEQ ID NO: 10;~~

~~(b3) the H chain variable region amino acid sequence described in SEQ ID NO: 21 and the L chain variable region amino acid sequence described in SEQ ID NO: 22.~~

12. (Previously presented) A composition comprising the antibody according to claim 2 and a pharmaceutically acceptable carrier.

13-19. (Canceled)

20. (Withdrawn – currently amended) A method for preventing and/or treating viral disease, malignant neoplasm, or immune disease, comprising the step of administering the antibody according to claim 2.

21-38. (Canceled)

39. (New) A composition comprising the antibody according to claim 7 and a pharmaceutically acceptable carrier.

40. (New) A composition comprising the antibody according to claim 9 and a pharmaceutically acceptable carrier.

41. (New) A composition comprising the antibody according to claim 10 and a pharmaceutically acceptable carrier.

42. (New) A composition comprising the antibody according to claim 11 and a pharmaceutically acceptable carrier.

43. (New) A method for preventing and/or treating viral disease, malignant neoplasm, or immune disease, comprising the step of administering the antibody according to claim 7.

44. (New) A method for preventing and/or treating viral disease, malignant neoplasm, or immune disease, comprising the step of administering the antibody according to claim 9.

45. (New) A method for preventing and/or treating viral disease, malignant neoplasm, or immune disease, comprising the step of administering the antibody according to claim 10.

46. (New) A method for preventing and/or treating viral disease, malignant neoplasm, or immune disease, comprising the step of administering the antibody according to claim 11.

47. (New) A method for preventing and/or treating a hepatitis C infection comprising the step of administering the antibody according to claim 2.

48. (New) A method for preventing and/or treating a hepatitis C infection comprising the step of administering the antibody according to claim 7.

49. (New) A method for preventing and/or treating a hepatitis C infection comprising the step of administering the antibody according to claim 9.

50. (New) A method for preventing and/or treating a hepatitis C infection comprising the step of administering the antibody according to claim 10.

51. (New) A method for preventing and/or treating a hepatitis C infection comprising the step of administering the antibody according to claim 11.

52. (New) A method for preventing and/or treating a hepatitis B infection comprising the step of administering the antibody according to claim 2.

53. (New) A method for preventing and/or treating a hepatitis B infection comprising the step of administering the antibody according to claim 7.

54. (New) A method for preventing and/or treating a hepatitis B infection comprising the step of administering the antibody according to claim 9.

55. (New) A method for preventing and/or treating a hepatitis B infection comprising the step of administering the antibody according to claim 10.

56. (New) A method for preventing and/or treating a hepatitis B infection comprising the step of administering the antibody according to claim 11.

57. (New) A method of dimerizing a heterodimeric type I interferon receptor, the method comprising contacting the heterodimeric type I interferon receptor with the antibody according to claim 2.

58. (New) A method of dimerizing a heterodimeric type I interferon receptor, the method comprising contacting the heterodimeric type I interferon receptor with the antibody according to claim 7.

59. (New) A method of dimerizing a heterodimeric type I interferon receptor, the method comprising contacting the heterodimeric type I interferon receptor with the antibody according to claim 9.

60. (New) A method of dimerizing a heterodimeric type I interferon receptor, the method comprising contacting the heterodimeric type I interferon receptor with the antibody according to claim 10.

61. (New) A method of dimerizing a heterodimeric type I interferon receptor, the method comprising contacting the heterodimeric type I interferon receptor with the antibody according to claim 11.